Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease
Aliment Pharmacol Ther
.
2015 Oct;42(7):939-40.
doi: 10.1111/apt.13335.
Authors
S Paul
1
,
X Roblin
2
,
L Peyrin-Biroulet
3
Affiliations
1
Laboratoire d'Immunologie et d'Immunomonitoring, CIC INSERM 1408 Vaccinologie, GIMAP EA3064, CHU de Saint-Etienne, Saint-Etienne, France.
2
Service de Gastrologie-Entérologie-Hépatologie, CHU de Saint-Etienne, Saint-Etienne, France. xavier.roblin@chu-st-etienne.fr.
3
Inserm U954 and Department of Gastroenterology, Nancy University Hospital, Henri Poincaré University, Vandoeuvre-lès-Nancy, France.
PMID:
26331560
DOI:
10.1111/apt.13335
No abstract available
Publication types
Letter
Comment
MeSH terms
Colitis, Ulcerative / drug therapy*
Crohn Disease / drug therapy*
Humans
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
Tumor Necrosis Factor-alpha